Nippon India Mutual Fund
When comparing, both lines start at 100. The fund's declared benchmark, a total-return index (dividends reinvested).
Up to one year: absolute. Longer: annualised. Category = median of Other ETF direct-plan Growth funds; index = NIFTY PHARMA TRI.
| Period | This fund | Category median | NIFTY PHARMA TRI | Rank in category |
|---|---|---|---|---|
| 1 month | -1.81% | -6.29% | -1.80% | — |
| 3 months | +4.67% | -4.21% | +4.74% | — |
| 6 months | +19.80% | +2.33% | +19.96% | — |
| 1 year | +21.50% | +2.08% | +21.80% | #3 of 28 Top 11% |
| 3 years | +19.93% | +10.23% | +20.24% | #2 of 16 Top 13% |
| 5 years | +13.09% | +7.89% | +13.34% | #3 of 14 Top 22% |
| 10 years | — | +10.95% | +9.42% | — |
| Since launch of NAV data | +12.78% | — | — | — |
| Window | High | Low |
|---|---|---|
| 1 month | 27.9198 | 26.8871 |
| 3 months | 27.9587 | 25.8486 |
| 6 months | 27.9587 | 22.3739 |
| 1 year | 27.9587 | 22.0529 |
A period is a dash when the fund has not existed that long or its NAV history has a hole at the start date — never a partial figure.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD | |
|---|---|---|---|---|---|---|---|
| This fund | — | — | -10.86% | +34.44% | +39.59% | -2.46% | +16.24% |
| Category median | +15.54% | +30.49% | +2.86% | +26.54% | +17.83% | +7.23% | -2.44% |
| NIFTY PHARMA TRI | +61.76% | +10.88% | -10.73% | +34.76% | +40.03% | -2.25% | +16.46% |
The fund's declared benchmark, a total-return index (dividends reinvested).
Twenty checks of five points each: performance, portfolio, operations, and risk against reward. Only checks we have data for are counted.
Risk-free rate 6.06% (3-year annualised return of the NSE 1-day (overnight) rate index). Benchmark-relative ratios use NIFTY PHARMA TRI. The fund's declared benchmark, a total-return index (dividends reinvested).
| Ratio | This fund | Category median | Against category |
|---|---|---|---|
| Sharpe ratio | 0.92 | 0.41 | Better |
| Sortino ratio | 1.33 | 0.47 | Better |
| Standard deviation | 15.08% | 16.03% | Better |
| Maximum drawdown | -16.55% | -20.97% | Better |
| Beta | 1.00 | 1.00 | — |
| R-squared | 100.0% | 100.0% | — |
| Jensen's alpha | -0.30% | -0.30% | Better |
| Treynor ratio | 13.88 | 6.05 | Better |
| Information ratio | -10.58 | -8.54 | Worse |
| Upside capture | 99.8% | 99.7% | Better |
| Downside capture | 100.1% | 100.0% | Worse |
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Healthcare | 20.75% | — | 146.5 |
| Divi's Laboratories Limited | Healthcare | 11.88% | — | 83.9 |
| Cipla Limited | Healthcare | 7.83% | — | 35.4 |
| Laurus Labs Limited | Healthcare | 7.36% | — | 122.5 |
| Torrent Pharmaceuticals Limited | Healthcare | 7.34% | — | 78.2 |
| Dr. Reddy's Laboratories Limited | Healthcare | 6.95% | — | 154.7 |
| Lupin Limited | Healthcare | 5.25% | — | 13.3 |
| Aurobindo Pharma Limited | Healthcare | 4.69% | — | 37.4 |
| Glenmark Pharmaceuticals Limited | Healthcare | 3.69% | — | 321.6 |
| Alkem Laboratories Limited | Healthcare | 3.08% | — | 28.9 |
| Biocon Limited | Healthcare | 2.90% | — | 597.3 |
| Zydus Lifesciences Limited | Healthcare | 2.87% | — | 33.3 |
| IPCA Laboratories Limited | Healthcare | 2.71% | — | 39.3 |
| Mankind Pharma Limited | Healthcare | 2.70% | — | 47.4 |
| Gland Pharma Limited | Healthcare | 2.27% | — | 34.3 |
| Sai Life Sciences Limited | Healthcare | 1.99% | — | 90.6 |
| Wockhardt Limited | Healthcare | 1.54% | — | 96.6 |
| Ajanta Pharma Limited | Healthcare | 1.50% | — | 44.9 |
| Abbott India Limited | Healthcare | 1.33% | — | 35.7 |
| Piramal Pharma Limited | Healthcare | 1.32% | — | 39.2 |
| Triparty Repo | — | 0.06% | — | — |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 0.21% · Nov 25 0.21% · Dec 25 0.21% · Jan 26 0.21% · Feb 26 0.21% · Mar 26 0.21% · Apr 26 0.21% · May 26 0.21% · Jun 26 0.21% · Jul 26 0.21% · Aug 26 0.24% · Sep 26 0.23%
Not Applicable
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
